Table 3.
Predictors for MCE and favorable outcome (mRS ≤ 3) in enrolled ABAO patients with cerebellar infarctions treated by EVT.
| MCE | Favorable outcome (mRS ≤ 3) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
| OR (95%CI) | p-value | Adjusted OR (95%CI) | p-value | OR (95%CI) | p-value | Adjusted OR (95%CI) | p-value | ||
| Age | 0.99 (0.97-1.01) | 0.435 | 0.99 (0.97-1.02) | 0.515 | |||||
| Sex | 1.63 (0.93-2.94) | 0.095 | 0.62 (0.36-1.10) | 0.099 | |||||
| Dyslipidemia | 1.10 (0.68-1.76) | 0.701 | 1.27 (0.76-2.11) | 0.355 | |||||
| Diabetes mellitus | 0.85 (0.49-1.45) | 0.561 | 0.61 (0.32-1.11) | 0.120 | |||||
| Hypertension | 1.10 (0.67-1.81) | 0.717 | 1.21 (0.71-2.10) | 0.496 | |||||
| Atrial fibrillation | 0.89 (0.48-1.59) | 0.689 | 1.23 (0.65-2.55) | 0.510 | |||||
| Lymphocyte | 0.90 (0.64-1.23) | 0.510 | 1.29 (0.92-1.80) | 0.130 | |||||
| Neutrophil count | 1.18 (1.11-1.27) | <0.001 | 1.17 (1.09-1.25) | <0.001 | 0.80 (0.73-0.86) | <0.001 | 0.83 (0.76-0.91) | <0.001 | |
| NLR | 1.01 (1.00-1.04) | 0.10 | 0.94 (0.89-0.97) | 0.003 | |||||
| SBP | 1.01 (0.99-1.01) | 0.187 | 1.00 (0.99-1.01) | 0.467 | |||||
| DBP | 1.00 (1.00-1.04) | 0.637 | 0.99 (0.98-1.01) | 0.298 | |||||
| TOAST | |||||||||
| LAA | Reference | NA | Reference | NA | |||||
| CE | 0.63 (0.35,1.10) | 0.109 | 1.59 (0.89,2.80) | 0.111 | |||||
| SOE | 0.62 (0.09,2.95) | 0.573 | 0.51 (0.03,3.07) | 0.536 | |||||
| SUE | 0.72 (0.27,1.79) | 0.498 | 1.43 (0.52,3.56) | 0.463 | |||||
| Occlusion Sites | |||||||||
| BA distal | Reference | NA | Reference | NA | Reference | NA | |||
| BA middle | 1.32 (0.73,2.39) | 0.360 | 0.44 (0.24,0.80) | 0.008 | 0.28 (0.12, 0.63) | 0.003 | |||
| BA proximal | 1.35 (0.66,2.72) | 0.403 | 0.44 (0.20,0.91) | 0.031 | 0.48 (0.17,1.25) | 0.140 | |||
| V4 | 2.23 (1.17,4.28) | 0.015 | 0.31 (0.14,0.63) | 0.002 | 0.29 (0.11,0.74) | 0.011 | |||
| Thrombolysis treatment | 0.98 (0.70-1.34) | 0.883 | 1.05 (0.74-1.48) | 0.762 | |||||
| Preonset mRS | 0.82 (0.49-1.32) | 0.428 | 0.69 (0.36-1.18) | 0.201 | |||||
| Onset to recanalization time | 1.00 (1.00-1.01) | 0.003 | 1.00 (1.00-1.00) | 0.005 | 1.00 (1.00-1.00) | 0.184 | |||
| NIHSS baseline | 1.06 (1.03-1.09) | <0.001 | 1.04 (1.01-1.07) | 0.013 | 0.91 (0.88,0.93) | <0.001 | 0.92 (0.89-0.95) | <0.001 | |
| PC-ASPECTS | 0.83 (0.72-0.96) | 0.011 | 1.70 (1.42,2.07) | <0.001 | 1.62 (1.29-2.06) | <0.001 | |||
| mTICI | 0.76 (0.65-0.88) | <0.001 | 0.80 (0.67-0.95) | 0.011 | 1.83 (1.46,2.35) | <0.001 | 1.74 (1.31-2.37) | <0.001 | |
| PC-CS score | 0.74 (0.65-0.84) | <0.001 | 0.77 (0.66-0.88) | <0.001 | 1.32 (1.16,1.5) | <0.001 | 1.22 (1.01,1.47) | 0.050 | |
PC-CS, posterior circulation collateral system score; BA, basilar artery; mTICI, modified thrombolysis in cerebral infarction; PCA, posterior cerebral artery; V4, V4 segment of vertebral artery; CE, cardioembolism; NIHSS, National Institutes of Health Stroke Scale; PC-ASPECTS, posterior circulation Alberta Stroke Program Early CT Score; SBP, systolic blood pressure; DBP, diastolic blood pressure; SOE, stroke of other determined cause; SUE, stroke of undetermined cause; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in Acute Stroke Treatment, NA, Not available.